Physician profile
Mark M Holt
NPI 1992708895
$239.60
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $87.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $41.71 | 2021 | |
| Lilly USA, LLC | $37.42 | 2022 | |
| Amgen INC. | $33.41 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.00 | 2021 | |
| Hospira, INC. | $27.07 | 2021 | |
| Tactile Systems Technology INC | $19.59 | 2021 | |
| Merck Sharp & Dohme LLC | $17.45 | 2021 | |
| Gilead Sciences, INC. | $16.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.43 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.07 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.